CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it was selected to receive a Biotech Investment Award from the Multiple Myeloma Research Foundation to support the research and development of ACE-011, a novel bone forming agent, for the treatment of multiple myeloma. In addition, Acceleron announced that it began a randomized, double-blind, placebo-controlled multiple ascending dose study of ACE-011.
